Display options
Cite
Cani AK, Dolce EM, Darga EP, et al. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Mol Oncol. 2021;doi: 10.1002/1878-0261.13150.
Cani, A. K., Dolce, E. M., Darga, E. P., Hu, K., Liu, C. J., Pierce, J., Bradbury, K., Kilgour, E., Aung, K., Schiavon, G., Carroll, D., Carr, T. H., Klinowska, T., Lindemann, J., Marshall, G., Rowlands, V., Harrington, E. A., Barrett, J. C., Sathiyayogan, N., Morrow, C., Sero, V., Armstrong, A. C., Baird, R., Hamilton, E., Im, S. A., Jhaveri, K., Patel, M. R., Dive, C., Tomlins, S. A., Udager, A. M., Hayes, D. F., & Paoletti, C. (2021). Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Molecular oncology, . https://doi.org/10.1002/1878-0261.13150
Cani, Andi K, et al. "Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection." Molecular oncology vol. (2021). doi: https://doi.org/10.1002/1878-0261.13150
Cani AK, Dolce EM, Darga EP, Hu K, Liu CJ, Pierce J, Bradbury K, Kilgour E, Aung K, Schiavon G, Carroll D, Carr TH, Klinowska T, Lindemann J, Marshall G, Rowlands V, Harrington EA, Barrett JC, Sathiyayogan N, Morrow C, Sero V, Armstrong AC, Baird R, Hamilton E, Im SA, Jhaveri K, Patel MR, Dive C, Tomlins SA, Udager AM, Hayes DF, Paoletti C. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection. Mol Oncol. 2021 Dec 06; doi: 10.1002/1878-0261.13150. Epub 2021 Dec 06. PMID: 34866317.
Copy Download .nbib Format: NLM
Share it on

Mol Oncol. 2021 Dec 06; doi: 10.1002/1878-0261.13150. Epub 2021 Dec 06.

Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.

Molecular oncology

Andi K Cani, Emily M Dolce, Elizabeth P Darga, Kevin Hu, Chia-Jen Liu, Jackie Pierce, Kieran Bradbury, Elaine Kilgour, Kimberly Aung, Gaia Schiavon, Danielle Carroll, T Hedley Carr, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Vicky Rowlands, Elizabeth A Harrington, J Carl Barrett, Nitharsan Sathiyayogan, Christopher Morrow, Valeria Sero, Anne C Armstrong, Richard Baird, Erika Hamilton, Seock-Ah Im, Komal Jhaveri, Manish R Patel, Caroline Dive, Scott A Tomlins, Aaron M Udager, Daniel F Hayes, Costanza Paoletti

Affiliations

  1. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
  2. Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
  3. Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
  4. Michigan Center for Translational Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
  5. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
  6. Cancer Research UK, Manchester Institute Cancer Biomarker Centre, University of Manchester, UK.
  7. Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  8. Late Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  9. Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA.
  10. Menarini Silicon Biosystems, Inc., San Diego, CA, USA.
  11. Department of Medical Oncology, The Christie NHS Foundation Trust and the Faculty of Biology, Medicine and Health, The University of Manchester, UK.
  12. Breast Cancer and Early Phase Clinical Trials Teams, Cancer Research UK, Cambridge Centre, UK.
  13. Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA.
  14. Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
  15. Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  16. Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA.

PMID: 34866317 DOI: 10.1002/1878-0261.13150

Abstract

Nearly all estrogen receptor (ER)-positive (POS) metastatic breast cancers become refractory to endocrine (ET) and other therapies, leading to lethal disease presumably due to evolving genomic alterations. Timely monitoring of the molecular events associated with response/progression by serial tissue biopsies is logistically difficult. Use of liquid biopsies, including circulating tumor cells (CTC) and circulating tumor DNA (ctDNA), might provide highly informative, yet easily obtainable, evidence for better precision oncology care. Although ctDNA profiling has been well investigated, the CTC precision oncology genomic landscape and the advantages it may offer over ctDNA in ER-POS breast cancer remain largely unexplored. Whole-blood (WB) specimens were collected at serial time points from patients with advanced ER-POS/HER2-negative (NEG) advanced breast cancer in a phase I trial of AZD9496, an oral selective ER degrader (SERD) ET. Individual CTC were isolated from WB using tandem CellSearch

© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Keywords: circulating tumor DNA; circulating tumor cells; liquid biopsy; precision medicine; tumor evolution; tumor heterogeneity

References

  1. Ngan RKC. Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers. Ann Transl Med. 2018;6:284. https://doi.org/10.21037/atm.2018.06.11 - PubMed
  2. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386-95. https://doi.org/10.1200/JCO.2002.10.058 - PubMed
  3. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594-600. https://doi.org/10.1200/JCO.2010.28.8415 - PubMed
  4. Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiowka M, Hewson N, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33:3781-7. https://doi.org/10.1200/JCO.2015.61.5831 - PubMed
  5. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446-51. https://doi.org/10.1038/ng.2823 - PubMed
  6. Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, et al. A First-in-human study of the new oral selective estrogen receptor degrader AZD9496 for ER(+)/HER2(-) advanced breast cancer. Clin Cancer Res. 2018;24:3510-8. https://doi.org/10.1158/1078-0432.CCR-17-3102 - PubMed
  7. Brown D, Smeets D, Szekely B, Larsimont D, Szasz AM, Adnet PY, et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017;8:14944. https://doi.org/10.1038/ncomms14944 - PubMed
  8. Yates LR, Knappskog S, Wedge D, Farmery JHR, Gonzalez S, Martincorena I, et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 2017;32:169-84.e7. https://doi.org/10.1016/j.ccell.2017.07.005 - PubMed
  9. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36:1631-41. https://doi.org/10.1200/JCO.2017.76.8671 - PubMed
  10. Taavitsainen S, Annala M, Ledet E, Beja K, Miller PJ, Moses M, et al. Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer. JCO Precis Oncol. 2019;3:1-9. https://doi.org/10.1200/po.19.00014 - PubMed
  11. Stetson D, Ahmed A, Xu X, Nuttall BRB, Lubinski TJ, Johnson JH, et al. Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis Oncol. 2019;3:1-9. https://doi.org/10.1200/po.18.00191 - PubMed
  12. McGranahan N, Favero F, de Bruin EC, Birkbak NJ, Szallasi Z, Swanton C. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015;7:283ra54. https://doi.org/10.1126/scitranslmed.aaa1408 - PubMed
  13. Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553-67. https://doi.org/10.1038/s41568-019-0180-2 - PubMed
  14. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216-24. https://doi.org/10.1038/onc.2015.192 - PubMed
  15. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-91. https://doi.org/10.1056/NEJMoa040766 - PubMed
  16. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420-30. https://doi.org/10.1200/JCO.2005.08.140 - PubMed
  17. Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106:dju066. https://doi.org/10.1093/jnci/dju066 - PubMed
  18. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-9. https://doi.org/10.1158/1078-0432.CCR-08-0872 - PubMed
  19. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213-21. https://doi.org/10.1200/JCO.2007.15.8923 - PubMed
  20. Cobain EF, Paoletti C, Smerage JB, Hayes DF. Clinical applications of circulating tumor cells in breast cancer. Recent Results Cancer Res. 2020;215:147-60. https://doi.org/10.1007/978-3-030-26439-0_8 - PubMed
  21. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30:525-32. https://doi.org/10.1200/JCO.2010.33.3716. - PubMed
  22. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556-63. https://doi.org/10.1200/JCO.2010.28.7045 - PubMed
  23. Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014;4:650-61. https://doi.org/10.1158/2159-8290.CD-13-1014 - PubMed
  24. Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Res. 2018;78:1110-22. https://doi.org/10.1158/0008-5472.CAN-17-2686 - PubMed
  25. Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, et al. Circulating biomarkers and resistance to endocrine therapy in metastatic breast cancers: correlative results from AZD9496 oral SERD phase I trial. Clin Cancer Res. 2018;24:5860-72. https://doi.org/10.1158/1078-0432.CCR-18-1569 - PubMed
  26. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-904. - PubMed
  27. Mesquita B, Rothwell DG, Burt DJ, Chemi F, Fernandez-Gutierrez F, Slane-Tan D, et al. Molecular analysis of single circulating tumour cells following long-term storage of clinical samples. Mol Oncol. 2017;11:1687-97. https://doi.org/10.1002/1878-0261.12113 - PubMed
  28. Peeters DJ, De Laere B, Van den Eynden GG, Van Laere SJ, Rothe F, Ignatiadis M, et al. Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from cell search enriched blood samples using dielectrophoretic cell sorting. Br J Cancer. 2013;108:1358-67. https://doi.org/10.1038/bjc.2013.92 - PubMed
  29. Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014;6:1371-86. https://doi.org/10.15252/emmm.201404033 - PubMed
  30. Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015;17:385-99. https://doi.org/10.1016/j.neo.2015.03.004 - PubMed
  31. Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, et al. Next-gen sequencing exposes frequent MED12 mutations and actionable therapeutic targets in phyllodes tumors. Mol Cancer Res. 2015;13:613-9. https://doi.org/10.1158/1541-7786.MCR-14-0578 - PubMed
  32. Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies. Oncotarget. 2017;8:7989-98. https://doi.org/10.18632/oncotarget.14008 - PubMed
  33. Harms PW, Hovelson DH, Cani AK, Omata K, Haller MJ, Wang ML, et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol. 2016;51:25-31. https://doi.org/10.1016/j.humpath.2015.12.015 - PubMed
  34. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol. 2014;41:297-9. https://doi.org/10.1053/j.seminoncol.2014.05.002 - PubMed
  35. Warrick JI, Hovelson DH, Amin A, Liu CJ, Cani AK, McDaniel AS, et al. Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma. Virchows Arch. 2015;466:297-311. https://doi.org/10.1007/s00428-014-1699-y - PubMed
  36. Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, et al. Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn. 2015;17:53-63. https://doi.org/10.1016/j.jmoldx.2014.09.008 - PubMed
  37. Harms KL, Lazo de la Vega L, Hovelson DH, Rahrig S, Cani AK, Liu CJ, et al. Molecular profiling of multiple primary merkel cell carcinoma to distinguish genetically distinct tumors from clonally related metastases. JAMA Dermatol. 2017;153:505-12. https://doi.org/10.1001/jamadermatol.2017.0507 - PubMed
  38. Parikh BA, Love-Gregory L, Duncavage EJ, Heusel JW. Identification of challenges and a framework for implementation of the AMP/ASCO/CAP classification guidelines for reporting somatic variants. Pract Lab Med. 2020;21:e00170. https://doi.org/10.1016/j.plabm.2020.e00170 - PubMed
  39. Miller CA, McMichael J, Dang HX, Maher CA, Ding L, Ley TJ, et al. Visualizing tumor evolution with the fishplot package for R. BMC Genom. 2016;17:880. https://doi.org/10.1186/s12864-016-3195-z - PubMed
  40. Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, et al. ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res. 2020;26:5172-7. https://doi.org/10.1158/1078-0432.CCR-20-0224 - PubMed
  41. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427-38.e6. https://doi.org/10.1016/j.ccell.2018.08.008 - PubMed
  42. Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, et al. Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol. 2020;4:442-65. https://doi.org/10.1200/po.19.00345 - PubMed
  43. Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380:1929-40. https://doi.org/10.1056/NEJMoa1813904 - PubMed
  44. Mroz EA, Rocco JW. The challenges of tumor genetic diversity. Cancer. 2017;123:917-27. https://doi.org/10.1002/cncr.30430 - PubMed
  45. De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2014;25:1729-35. https://doi.org/10.1093/annonc/mdu239 - PubMed
  46. Tarabichi M, Salcedo A, Deshwar AG, Ni Leathlobhair M, Wintersinger J, Wedge DC, et al. A practical guide to cancer subclonal reconstruction from DNA sequencing. Nat Methods. 2021;18:144-55. https://doi.org/10.1038/s41592-020-01013-2 - PubMed
  47. Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, et al. The mutational landscape of circulating tumor cells in multiple myeloma. Cell Rep. 2017;19:218-24. https://doi.org/10.1016/j.celrep.2017.03.025 - PubMed
  48. Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207-18. https://doi.org/10.1056/NEJMoa2017699 - PubMed
  49. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353-65. https://doi.org/10.1016/S1470-2045(20)30445-9 - PubMed
  50. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328-39. https://doi.org/10.1056/NEJMoa1917346 - PubMed
  51. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92. https://doi.org/10.1056/NEJMoa1113205 - PubMed
  52. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-8. https://doi.org/10.1126/science.959840 - PubMed
  53. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32:479-84. https://doi.org/10.1038/nbt.2892 - PubMed
  54. Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, et al. Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis. Clin Cancer Res. 2018;24:5635-44. https://doi.org/10.1158/1078-0432.CCR-18-0862 - PubMed
  55. Gao Y, Ni X, Guo H, Su Z, Ba Y, Tong Z, et al. Single-cell sequencing deciphers a convergent evolution of copy number alterations from primary to circulating tumor cells. Genome Res. 2017;27:1312-22. https://doi.org/10.1101/gr.216788.116 - PubMed
  56. Paolillo C, Mu Z, Rossi G, Schiewer MJ, Nguyen T, Austin L, et al. Detection of activating estrogen receptor gene (ESR1) mutations in single circulating tumor cells. Clin Cancer Res. 2017;23:6086-93. https://doi.org/10.1158/1078-0432.CCR-17-1173 - PubMed
  57. Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, et al. Chromosomal aberrations associated with sequential steps of the metastatic cascade in colorectal cancer patients. Clin Chem. 2018;64:1505-12. https://doi.org/10.1373/clinchem.2018.289819 - PubMed
  58. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature. 1980;283:139-46. https://doi.org/10.1038/283139a0 - PubMed
  59. Romano E, Pradervand S, Paillusson A, Weber J, Harshman K, Muehlethaler K, et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res. 2013;19:5749-57. https://doi.org/10.1158/1078-0432.CCR-13-0661 - PubMed
  60. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17:77-88. https://doi.org/10.1016/j.ccr.2009.11.022 - PubMed
  61. Frei E 3rd, Holland JF, Schneiderman MA, Pinkel D, Selkirk G, Freireich EJ, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13:1126-48. - PubMed
  62. Paoletti C, Miao J, Dolce EM, Darga EP, Repollet MI, Doyle GV, et al. Circulating tumor cell clusters in patients with metastatic breast cancer: a SWOG S0500 translational medicine study. Clin Cancer Res. 2019;25:6089-97. https://doi.org/10.1158/1078-0432.CCR-19-0208 - PubMed
  63. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32:3483-9. https://doi.org/10.1200/JCO.2014.56.2561 - PubMed
  64. Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110-22. https://doi.org/10.1016/j.cell.2014.07.013 - PubMed
  65. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670-91. https://doi.org/10.1016/j.cell.2016.11.037 - PubMed
  66. Kim TH, Wang Y, Oliver CR, Thamm DH, Cooling L, Paoletti C, et al. A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. Nat Commun. 2019;10:1478. https://doi.org/10.1038/s41467-019-09439-9 - PubMed
  67. Fehm TN, Meier-Stiegen F, Driemel C, Jager B, Reinhardt F, Naskou J, et al. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytometry A. 2018;93:1213-9. https://doi.org/10.1002/cyto.a.23669 - PubMed
  68. Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz N, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci USA. 2013;110:16580-5. https://doi.org/10.1073/pnas.1313594110 - PubMed
  69. Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al. A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: results from the MYSTIC study. Clin Cancer Res. 2021;27:1631-40. https://doi.org/10.1158/1078-0432.CCR-20-3771 - PubMed

Publication Types

Grant support